Home Cart Sign in  
Chemical Structure| 73536-69-3 Chemical Structure| 73536-69-3

Structure of Bifendate
CAS No.: 73536-69-3

Chemical Structure| 73536-69-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bifendate can reduce the activity of alanine aminotransferase and attenuate alanine aminotransferase hepatic steatosis. It is used as an anti-HBV agent.

Synonyms: DDB

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bifendate

CAS No. :73536-69-3
Formula : C20H18O10
M.W : 418.35
SMILES Code : C2=C(OC)C1=C(OCO1)C(=C2C(OC)=O)C3=C(C=C(OC)C4=C3OCO4)C(OC)=O
Synonyms :
DDB
MDL No. :MFCD01751431
InChI Key :JMZOMFYRADAWOG-UHFFFAOYSA-N
Pubchem ID :108213

Safety of Bifendate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice CCl4-induced acute and chronic liver injury models Oral 200 mg/g Once a day for 7 days Bifendate significantly reduced CCl4-induced liver injury and transaminase levels. J Anim Sci Biotechnol. 2023 Apr 10;14(1):56
Sprague-Dawley (SD) rats CCl4-induced acute liver injury model Oral administration 200 mg/kg 7 days To study the protective effects and mechanisms of Bifendate against CCl4-induced acute liver injury. Results showed that Bifendate significantly alleviated inflammatory lesions in liver tissues, decreased levels of COX-2, PGE2, and γ-GT, increased indices of SOD, GSH-Px, CAT, T-AOC, and TP, and reduced MDA content. Molecules. 2022 Mar 29;27(7):2224
Kunming mice CCl4-induced acute hepatotoxicity model and BCG + LPS-induced immunological liver injury model Oral 0.40 g/kg body weight Once daily for 7 consecutive days As a positive control, to evaluate the protective effects of Bifendate against CCl4 and BCG + LPS-induced liver injury. Results showed that Bifendate significantly reduced the levels of AST, ALT, and TBIL. Chin Med. 2012 Sep 29;7(1):21
Kunming mice Acute liver injury model Oral 100 mg/kg Once daily for 7-10 days Bifendate significantly reduced serum ALT and AST activities, decreased MDA content in liver tissue, increased SOD and GSH-px activities, and alleviated liver tissue pathological damage. World J Gastroenterol. 2005 May 21;11(19):2984-9
Wistar rats CCl4-induced liver injury model Gavage 100 mg/kg Once daily for 28 days Bifendate significantly attenuated the CCl4-induced elevation of serum AST, ALT, ALP activities and restored serum TP, Alb, G levels, reduced hepatic fatty degeneration and necrosis, decreased liver index and hydroxyproline levels, inhibited lipid peroxidation, and enhanced antioxidant enzyme activities. Molecules. 2011 Oct 17;16(10):8684-94

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.95mL

2.39mL

1.20mL

23.90mL

4.78mL

2.39mL

References

 

Historical Records

Categories